These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 22047702)

  • 1. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
    Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
    Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
    Eagye KJ; Nicolau DP
    Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
    Cook PP; Gooch M; Rizzo S
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5597-601. PubMed ID: 21968357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
    Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
    Beović B; Kreft S; Seme K; Cizman M
    J Chemother; 2011 Aug; 23(4):216-20. PubMed ID: 21803699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
    McDougall DA; Morton AP; Playford EG
    J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
    Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
    Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
    Livermore DM; Mushtaq S; Warner M
    J Antimicrob Chemother; 2005 Mar; 55(3):306-11. PubMed ID: 15705643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
    dos Santos RP; Jacoby T; Goldani LZ
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3076; author reply 3076-7. PubMed ID: 20554969
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO; Mazumder SA
    J Antimicrob Chemother; 2009 Jun; 63(6):1297-9. PubMed ID: 19369268
    [No Abstract]   [Full Text] [Related]  

  • 18. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
    Ho CM; Ho MW; Liu YC; Toh HS; Lee YL; Liu YM; Huang CC; Lu PL; Liu CE; Chen YH; Ko WC; Tang HJ; Yu KW; Chen YS; Chuang YC; Wang JH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S24-8. PubMed ID: 22749055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
    Sousa D; Castelo-Corral L; Gutiérrez-Urbón JM; Molina F; López-Calviño B; Bou G; Llinares P
    J Antimicrob Chemother; 2013 Aug; 68(8):1917-25. PubMed ID: 23557925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.